Immunotherapy Drives Mesenchymal Transition and Tumor Microenvironment Immune Response in Glioblastoma Introduction Glioblastoma is a highly malignant brain tumor with no curative treatment currently available. Although immunotherapy has shown efficacy in other cancer types, the response in glioblastoma patients is limited. Investigating the effect...

Introduction Chordoma is a rare and locally aggressive mesenchymal tumor, believed to originate from the remnant tissues of the primitive notochord. The incidence of chordoma is approximately 0.8 per million, with a predilection for the sacral and skull base regions. Currently, the optimal treatment strategy is maximal safe surgical resection follo...

The human genome-encoded triggering receptor expressed on myeloid cells 2 (TREM2) was initially thought to play a role primarily in the central nervous system, participating in the functional regulation of microglia. In recent years, researchers have found that TREM2 is also expressed in peripheral tumors and may promote tumor progression. However,...

Title: Treating Low-Grade Optic Pathway Glioma by Inhibiting Neuronal Activity Introduction: Optic pathway glioma (OPG) is a low-grade glioma commonly found in children with neurofibromatosis type 1 (NF1). NF1 is a common neurocutaneous syndrome with an incidence of approximately 1⁄3000. Although OPG is a low-grade tumor, it can lead to serious com...